Alexion Pharmaceuticals Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Alexion Pharmaceuticals Inc.
Dealmaking Quarterly Statistics, Q1 2021: Boston Scientific, Roche Start The Year With Billion-Dollar-Plus Acquisitions
During the first quarter, medical device company mergers and acquisition totalled $10.2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $5bn.
Novavax said it would start shipping supplies of its vaccine to Europe starting in late 2021, while Vaxart delayed the start of its Phase II study due to issues with Emergent BioSolutions. Meanwhile, Roche India received an EUA for Regeneron's antibody cocktail
Health care delivery has been transformed over the past decade, and so has Royal Philips, whose CEO Frans van Houten explains why both were necessary, and the extra impetus for system-wide change following the COVID-19 pandemic.
Pascal Soriot said AZ employees should be proud of the COVID-19 vaccine achievements so far, but conceded that manufacturing output would continue to lag.
- Large Molecule
- Other Names / Subsidiaries
- Alexion Pharma K.K. (formerly Legend K.K. or Legend Pharma Co., Ltd.) (Japan)
- Enobia Pharma Corp.
- Portola Pharmaceuticals, Inc. (PTLA)
- Synageva BioPharma Corp.
- Syntimmune, Inc.
- Taligen Therapeutics, Inc.
- Wilson Therapeutics AB